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Abstract
Background: The prevalence of hyperglycemia among HIV-infected persons who are not receiving antiretroviral
therapy is unknown. We conducted a cross-sectional survey to estimate the prevalence of hyperglycemia among
Chinese adults with newly diagnosed HIV/AIDS.
Methods: Two thousand and six newly diagnosed HIV/AIDS patients from 10 provinces and municipalities in China
were selected during 2009 to 2010. After an overnight fast, serum samples were collected to measure glucose
concentrations. Demographics and medical histories were recorded. Factors associated with the presence of
diabetes were analysed by logistic regression.
Results: Among the 2006 patients, 75.67% were male. Median age was 40 years (range: 18–86 years). 19.99% had
hyperglycemia, 9.47% had impaired fasting glucose (IFG) and 10.52% had diabetes. The prevalences of
hyperglycemia, of IFG and of diabetes were 21.54%, 10.28% and 11.27% among men and 15.16%, 6.97% and 8.20%
among women, respectively. The prevalence of diabetes increased with increasing age (7.00%, 13.36% and 21.21%
among patients who were 18–40, 40–60, and ≥60 years of age respectively) and with decreasing CD4 count (6.74%,
8.45%, 9.69%, and 12.66% among patients with CD4 count of ≥350, 200–350, 50–200, and < 50/mm3 respectively).
The prevalence of diabetes was higher among ethnic minority patients than among the Han patients (14.37%
versus 9.24%). The logistic analysis showed that older age, lower CD4 count and minority ethnicity were
significantly associated with an increased risk of diabetes.
Conclusions: Hyperglycemia is highly prevalent among Chinese adults with newly diagnosed HIV/AIDS. Older age,
lower CD4 count and minority ethnicity are associated with increased risk of diabetes. All newly diagnosed HIV/
AIDS individuals should be routinely evaluated for hyperglycemia.
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Background
AIDS is one of the major public health problems in
China. With the widespread use of antiretroviral therapy
(ART) in clinical practice, the prognosis and quality of
life of HIV/AIDS patients have been significantly impro-
ved, and mortality and morbidity from HIV and its com-
plications have dramatically declined [1]. However, the
incidence of some non-AIDS-related diseases such as
cardiovascular diseases shows a rising trend, and these
diseases have become a major cause of illness in patients
with HIV [2-4].
Abnormal glucose metabolism that occurs during the
course of HIV infection and its treatment is a prevalent
condition [5]. Diabetes is a known complication of ART,
being associated with exposure to some antiretroviral
drugs [6,7]. The reported prevalence of diabetes in
HIV-infected populations ranges from 2% to 14%, with
differences in prevalence explained by differences in
demographic characteristics, lifestyle, and antiretroviral
exposure [7]. With the aging of the HIV-positive popula-
tion, brought about by an increased life expectancy after
the widespread use of ART, the prevalence of diabetes is
likely to increase. To date, the reported prevalence of
diabetes has only been estimated among the popula-
tion receiving ART, the prevalence and the associated
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risk factors for diabetes among newly diagnosed HIV/
AIDS patients without ART exposure have not been
determined.
Diabetes has become a major public health problem
in China. A national survey conducted in 2008, involving
46,239 Chinese adults, 20 years of age or older, from 14
provinces and municipalities, showed that the age-stan-
dardized prevalence of total diabetes and of pre-diabetes
were 9.7% and 15.5%, respectively [8]. However, so far
the prevalence of hyperglycemia among newly diagnosed
HIV/AIDS patients in China has not been extensively
studied. Accordingly, the purpose of the present study
was to estimate the prevalence of hyperglycemia among
adults with newly diagnosed HIV/AIDS in China, and to
identify demographic and HIV-related factors that were
associated with the presence of diabetes.
Methods
Study population
We conducted a cross-sectional survey on HIV/AIDS
in China’s HIV epidemic provinces and municipalities
including Guangxi, Yunnan, Henan, Xinjiang, Jiangxi,
Guangdong, Shaanxi, Hunan, Heilongjiang and Shanghai
during 2009 to 2010. The survey subjects were newly
diagnosed HIVAIDS patients who had not received
ART. Subjects aged 18 years or more at the time of en-
rolment with documented HIV-1 infection were eligible
for this study. Only antiretroviral naïve subjects were
included in the study. Being on ART was an exclusion
criterion. Antiretroviral experienced but currently un-
treated subjects were not eligible for this study. All
patients were confirmed to be positive for HIV antibody
through laboratory detection, and the diagnosis was in
line with national HIV/AIDS diagnostic criteria.
Blood samples
After at least 10 hours of overnight fasting, a venous
blood specimen was collected in a vacuum tube contai-
ning sodium fluoride, for the measurement of plasma
glucose. Written informed consent was obtained for all
subjects; consent forms and procedures, as well as sur-
vey protocol, were approved by the Shanghai Public
Health Clinical Center Ethics Committee. Plasma glu-
cose was measured with the use of a hexokinase enzym-
atic method, at the clinical biochemical laboratories in
each province. All the study laboratories successfully
completed a standardization and certification program.
Study-outcome definitions
Results of plasma glucose testing were categorized as fol-
lows: hyperglycemia (fasting glucose level ≥ 6.1 mmol/l
[110 mg/dl]), impaired fasting glucose (IFG) (fasting
glucose level ≥ 6.1 mmol/l [110 mg/dl] and <7.0 mmol/l
[126 mg/dl]), and diabetes (fasting glucose level ≥7.0 mmol/l
[126 mg/dl]). Hyperglycemia was thus defined as ei-
ther IFG or diabetes.
Data collection
Data were collected according to standardised criteria.
On enrolment, standardised data collection forms were
completed at the sites providing information from pa-
tient interview and patient case notes. Data collected on
newly identified cases included demographic informa-
tion, risk-behavior information (injection drug use, his-
tory of heterosexual or homosexual sex, receipt of blood
transfusion), and laboratory test results. Variables of inter-
est included age, sex, race, ethnicity, HIV transmission
route, and CD4 count. Age was denoted as <40, 40–60 or
≥60 years. Race/ethnicity was designated as Han or other
(minority groups). HIV transmission route was categor-
ized as sexual contact (including homosexual or hetero-
sexual), blood (including blood transfusion or injection
drug use), or unknown transmission risk. CD4 count was
denoted as <50, 50–200, 200–350 or ≥350/mm3.
Statistical analysis
SPSS software for Windows (version 11.5) was used for
statistical analysis. A chi-square test was applied for cat-
egorical attributes. We evaluated if the prevalence of dia-
betes increased with decreasing CD4 count using a chi-
square test for trend. Multivariate logistic regression
models were used to analyze the association between dia-
betes and relevant covariates. All variables included in the
models were determined a priori based on epidemiological
importance and biological plausibility. Variables included
in the models were age, sex, ethnicity, CD4 count, and
HIV transmission route. Primary analysis was done based
on all persons who met inclusion criteria. Sensitivity ana-
lyses were performed for patients who had a baseline CD4
count available. The statistical test was two-tailed and per-
formed at a level of statistical significance of 0.05.
Results
Patient characteristics
We included a total of 2006 adults with newly diagnosed
HIV/AIDS. Table 1 describes the basic characteristics of
the study population. The study sample was primarily
male (75.67%), the median age was 40 years (41 years for
males, 38 years for females), 24.47% were ethnic minor-
ities, and the median CD4 count was 136 cells/mm3. Most
patients acquired HIV through sexual contact (73.73%).
Prevalence of hyperglycemia among men and women
with HIV/AIDS
Figure 1 describes the prevalence of hyperglycemia, of IFG
and of diabetes among men and women with HIV/AIDS.
Among the 2006 patients, 401 (19.99%) had hyperglycemia,
190 (9.47%) had IFG, 211 (10.52%) had diabetes. Among
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1518 male patients, 327 (21.54%) had hyperglycemia, 156
(10.28%) had IFG, and 171 (11.27%) had diabetes; among
488 female patients, 74 (15.16%), 34 (6.97%) and 40 (8.20%)
had hyperglycemia, IFG and diabetes respectively. The
prevalence of hyperglycemia and of IFG among men were
significantly higher than those among women (P = 0.002,
P = 0.030), the prevalence of diabetes was slightly higher
among men than among women (P = 0.055).
Prevalence of hyperglycemia in patients with different
CD4 count
Figure 2 describes the prevalence of hyperglycemia, of
IFG and of diabetes among patients with different CD4
counts. The prevalence of IFG was 8.43%, 9.54%, 8.40%,
and 9.80% among patients with CD4 counts of ≥ 350,
200–350, 50–200, and < 50/mm3, respectively. The pre-
valence of IFG did not differ significantly according to
CD4 count (P = 0.801). The prevalence of diabetes was
6.74%, 8.45%, 9.69%, and 12.66% among patients with
CD4 counts of ≥ 350, 200–350, 50–200, and < 50/mm3,
respectively. The prevalence of diabetes increased with
decreasing CD4 count (P = 0.032).
Prevalence of hyperglycemia among men and women
with different age
Figure 3 and Figure 4 describe the prevalence of diabetes
and of IFG among adults according to age. The preva-
lence of diabetes was 7.00%, 13.36% and 21.21% among
patients who were 18–40, 40–60, and ≥ 60 years of age,
respectively. The prevalence of diabetes increased with
Table 1 Basic characteristics of 2006 newly diagnosed
HIV/AIDS patients in China
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Figure 1 Prevalence of hyperglycemia, IFG and diabetes among




























Figure 2 Prevalence of hyperglycemia, IFG and diabetes among
patients with different CD4+T lymphocyte count (1970 patients




























Figure 3 Prevalence of diabetes among men and women
according to age.
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increasing age (P < 0.001). The prevalence of IFG was
8.27%, 10.80% and 11.52% among patients who were
18–40, 40–60, and ≥ 60 years of age, respectively. The
prevalence of IFG did not differ significantly according
to age (P = 0.125).
Prevalence of hyperglycemia in patients according to
ethnicity
The prevalence of diabetes was 9.24% and 14.37% among
the Han patients and ethnic minority patients, respect-
ively. The prevalence of diabetes among ethnic minority
patients was higher than that among the Han patients
(P = 0.001). The prevalence of IFG was 9.50% and 9.38%
among the Han patients and ethnic minority patients,
respectively. The prevalence of IFG did not differ signifi-
cantly according to ethnicity (P = 0.936).
Risk factors for diabetes among adults with newly
diagnosed HIV/AIDS
In a multivariate analysis using a logistic regression mo-
del, we analyzed factors associated with the presence
of diabetes. Table 2 summarizes the results of the final
regression model. Older age, lower CD4 count and mi-
nority ethnicity were significantly associated with an in-
creased risk of diabetes. HIV transmission route and
sex failed to show an association with the presence of
diabetes.
Discussion
A national survey of the general adult population in
2008 showed that the prevalence of total diabetes and of
pre-diabetes among all Chinese adults was 9.7% and
15.5%, respectively [8]. Our study showed that the preva-
lence of diabetes and of IFG among Chinese adults with
newly diagnosed HIV/AIDS was 10.52% and 9.47% re-
spectively, which suggests that hyperglycemia is also
relatively prevalent among newly diagnosed HIV/AIDS
patients in China. It also showed that among patients
aged 18–40 years the prevalence of diabetes was 7.00%
and of IFG 8.27%, indicating that hyperglycemia is even
common among the younger newly diagnosed HIV-
infected patients. At present, the number of HIV/AIDS
patients is still on the rise in China [9]. With the
growing number of people living with HIV/AIDS, the
number of persons with hyperglycemia and HIV/AIDS
is expected to increase. Therefore, newly diagnosed
HIV/AIDS patients should be screened for hypergly-
cemia and this should become an important part of
HIV care in China.
Our study showed that there was a high prevalence of
diabetes among adults with newly diagnosed HIV/AIDS,
and that lower CD4 count was associated with an in-
creased risk of diabetes, since the prevalence of diabetes
increased with decreasing CD4 count. This suggests that
the presence of diabetes may be related to HIV infection.
The underlying cause and origin of diabetes in HIV/
AIDS patients may differ from that of the general popu-
lation [7]. Our study population was newly diagnosed
HIV/AIDS patients who had not received ART, hence
hyperglycemia among these patients was not caused by
antiretroviral drugs. Although the etiology of glucose di-
sorders in HIV persons remains unknown and no study
has yet directly confirmed that HIV infection may cause
hyperglycemia, current studies have shown that HIV in-
fection is related to cardiovascular diseases and metabolic
disorders. Severity of HIV disease has been associated
with increased risk of lipo-atrophy, lipo-dystrophy, and
cardiovascular disease [10-14]. Together with our study,
these associations suggest that HIV-related factors prob-
ably contribute to the pathogenesis of IFG and diabetes in
HIV-infected patients not using ART. However, our study
cannot fully confirm that HIV infection results in hy-
perglycemia. Therefore, the contribution of HIV-related





























Figure 4 Prevalence of IFG among men and women according
to age.
Table 2 Identification of risk factors for the presence of
diabetes, results of the regression model
Risk factor P value Odds ratio 95%
Confidence
interval
Age,per 20-year increment <0.001 1.961 (1.587, 2.422)
CD4 count, per decrease of
150 cells/mm3
0.017 1.225 (1.036, 1.448)
Minority ethnicity 0.004 1.600 (1.160, 2.207)
Sex 0.165 0.764 (0.523, 1.117)
HIV transmission route
Sexual contact 0.606 1.000 –
Blood 0.404 0.809 (0.491, 1.332)
Unknown transmission risk 0.326 0.731 (0.391, 1.366)
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Our study showed that prevalence of diabetes increa-
sed with increasing age. Older age was significantly asso-
ciated with an increased risk of diabetes, increasing the
odds by a factor of 1.961. This indicates that older age is
a risk factor for diabetes among adults with newly diag-
nosed HIV/AIDS. Glycemic markers should be moni-
tored regularly in aging HIV-infected patients.
In this study population, the prevalence of IFG was
significantly higher among men than among women,
and the prevalence of diabetes was slightly higher among
men than among women. In addition, the prevalence of
diabetes was significantly higher among ethnic minority
patients than among the Han patients. Minority ethni-
city was significantly associated with an increased risk of
diabetes, increasing the odds by a factor of 1.600. How-
ever, we did not find a significant association between
gender and the presence of diabetes among newly diag-
nosed HIV/AIDS patients by a logistic regression model;
HIV transmission route also failed to show association
with the presence of diabetes.
The abnormal glucose metabolism that occurs during
the course of ART for HIV has gained much attention in
recent years. At present, attention is focused on the rela-
tionship between ART and the presence of diabetes.
Current studies show a significant relationship between
new-onset diabetes and exposure to ART; the incidence
of diabetes increased with cumulative exposure to ART.
A study showed that the incidence of diabetes in HIV-
infected men with ART exposure was greater than four
times that of HIV-seronegative men [15]. A Swiss HIV
cohort study showed that the incidence of diabetes in
patients receiving ART was 4.42 cases per 1000 person-
years of follow-up [16]. That study found that current
treatment with protease inhibitor- and nucleoside rever-
se-transcriptase inhibitor-containing regimens was asso-
ciated with the risk of developing type 2 diabetes [16].
Another study demonstrated that stavudine and zidovu-
dine are significantly associated with diabetes after ad-
justment for risk factors for diabetes and lipids [6]. A
French study showed that the incidence of diabetes in
patients receiving ART was 14.1 cases per 1000 person-
years of follow-up, and that the occurrence of diabetes
was not associated with HIV-related markers [17]. Al-
though antiretroviral drugs have a direct role in the
pathogenesis of hyperglycemia in HIV patients, some
studies suggest that HIV disease may also be associated
with the development of hyperglycemia [5]. One study
showed that HIV-infected men with lower nadir CD4
cell counts had an increased risk of incident glucose ab-
normalities compared with those with higher nadir CD4
cell counts after initiating HIV treatment [15].
Some limitations to our study should be noted. First,
potential sample selection bias may have affected the
findings. China is a country with a large territory and an
extremely large population. The HIV epidemic is serious
in some areas and among some most-at-risk popula-
tions. There may exist differences in prevalence of hy-
perglycemia among patients with different demographic
characteristics and lifestyle. Second, some studies have
demonstrated body-mass index, lifestyle, and family his-
tory of hyperglycemia are associated with the prevalence
of IFG and diabetes [6,8,15], but these factors were not
assessed in our study. Therefore, we were not able to de-
termine the association between these factors and the
prevalence of hyperglycemia. Furthermore, if these vari-
ables had been controlled for, some variables such as
CD4 count may not have remained significant in the lo-
gistic regression model. Third, impaired glucose toler-
ance (IGT) and early insulin resistance are particularly
prevalent in HIV patients (10%-25%), especially in those
receiving ART containing protease inhibitors [18]. How-
ever, we did not do an oral glucose-tolerance test for the
patients, thus we can not estimate the prevalence of IGT
in HIV patients. In this study, we used only one fasting
glucose level to diagnose diabetes, this may have led to
over-reporting of the true prevalence of diabetes. In
addition, the design of the study was observational; we
were able to examine potential associations but were un-
able to assess causation, so it is not clear if the diabetes
preceded the HIV infection or vice versa.
Conclusions
Hyperglycemia is highly prevalent among adults with
newly diagnosed HIV/AIDS in China. Older age, lower
CD4 count and minority ethnicity are associated with in-
creased risk of diabetes. It is necessary to routinely screen
IFG and diabetes among newly diagnosed HIV/AIDS pa-
tients. We strongly recommend that all newly diagnosed
HIV/AIDS patients should be routinely evaluated for hy-
perglycemia both before and after initiating HIV treat-
ment. Further research is needed to explore the impact of
HIV infection on the development of hyperglycemia in
HIV-infected patients.
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